Flagship Pioneering related stories
All articles and analysis
Rubius Therapeutics goes publicCambridge, Massachusetts-based Rubius Therapeutics, a creator of cellular therapies, has debuted its IPO after pricing its over 10.4 million shares at $23 per share. The stock began trading July 18, 2018 on the NASDAQ under the ticker symbol "RUBY." J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners are the lead underwriters. Rubius' pre-IPO backers include Flagship Pioneering.
- Otsuka to buy VC-backed Visterra for about $430 mln
Otsuka has agreed to acquire Visterra, a developer of antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases, for about $430 million in cash. The deal is expected to close in the third quarter of this year. Visterra is backed by Polaris Partners, Flagship Pioneering, the Bill and Melinda Gates Foundation, MRL Ventures Fund, Vertex Ventures HC, Serum Institute of India Private Ltd., Temasek Holdings, Omega Funds, Cycad Group, Lux Capital, Alleghany Financial Group Ventures, CTI Life Sciences Fund and Alexandria Equities.
- VC-backed Evelo Biosciences goes public
Cambridge, Massachusetts-based Evelo Biosciences, a biotech company, has raised $85 million for its IPO after pricing its 5.3 million shares at $16 per share. The stock began trading May 9, 2018 on the NASDAQ under the ticker symbol "EVLO." Morgan Stanley, Cowen and BMO Capital Markets are the lead underwriters. Evelo's pre-IPO backers included Flagship Pioneering, GV, Celgene, Mayo Clinic and Alexandria Venture Investments.
- Flagship Pioneering provides $50 mln to Foghorn Therapeutics
Cambridge, Massachusetts-based Foghorn Therapeutics, a developer of therapies for cancer and other serious diseases, has secured $50 million in funding. The investor was Flagship Pioneering.
- Flagship Pioneering expands senior leadership team with two new appointments
Flagship Pioneering has added two to its senior leadership team. Rob Rosiello is joining as executive partner and chief operating office while Jason Pontin is a senior partner and chief editor. The Cambridge, Massachusetts-based venture firm invests in the health and sustainability sectors.
- Flagship Pioneering nabs $618 mln for sixth fund
Flagship Pioneering has raised $618 million for its sixth fund, according to an SEC filing https://www.sec.gov/Archives/edgar/data/1716926/000171692617000002/xslFormDX01/primary_doc.xml The Cambridge, Massachusetts-based venture firm invests in the health and sustainability sectors.